The body mass index (BMI), a traditional indicator of general obesity, was reported to be associated with better overall survival (OS) and progression-free survival (PFS) in mRCC patients receiving anti-VEGF therapies [7]. This evidence concerns the gene VEGFA and obesity due to melanocortin 4 receptor deficiency.